Skip to main content
Fig. 1 | Molecular Medicine

Fig. 1

From: The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD)

Fig. 1

Protein and mRNA expression of β3-AR in the liver in the four groups. a Quantitative analysis of β3-AR protein levels relative to GAPDH levels (each group, n = 8). b Western blot analysis of β3-AR protein levels using specific β3-AR antibodies. GAPDH was used as a loading control. c β3-AR mRNA expression in the control, HFD, HFD + β3-AGO and HFD + β3-ANT groups (each group, n = 8). β3-AGO refers to the β3-AR agonist BRL37344, and β3-ANT refers to the β3-AR antagonist L748337. *P < 0.05 vs the control group, #P < 0.05 vs the HFD group

Back to article page

Molecular Medicine

ISSN: 1528-3658